• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Eu­ro­pean reg­u­la­tors ex­pand use of Ab­b­Vie's two-month hep C reg­i­men

6 years ago
Pharma

Tiny Treve­na re­turns to FDA in sec­ond bid for con­tro­ver­sial opi­oid painkiller

6 years ago
FDA+

Ahead of cru­cial PhII read­out, Sh­iono­gi lines up an op­tion to buy out biotech part­ner and its non-amy­loid Alzheimer's ...

6 years ago
Deals

Abrax­ane de­vel­op­er Igle­sias joins Sen­ti Bio­sciences; AB2Bio re­cruits CEO

6 years ago
Peer Review

Se­ri­ous side ef­fects side­line small Roche study of an ex­per­i­men­tal Hunt­ing­ton’s drug from Io­n­is

6 years ago
R&D

Lob­by­ing cam­paign killed pro­pos­al to set price lim­its on fu­ture coro­n­avirus drugs, vac­cines — re­port

6 years ago
R&D
Coronavirus

Dana-Far­ber, MD An­der­son, MIT im­pose trav­el re­stric­tions amid broad­er ef­forts to con­tain coro­n­avirus dam­age in US

6 years ago
Coronavirus

As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ...

6 years ago
R&D
Pharma

Three Bio­gen staffers test pos­i­tive for coro­n­avirus in wake of Boston ho­tel meet­ing

6 years ago
Coronavirus

More than half of its gross sales ul­ti­mate­ly went to pay­ers as re­bates, Sanofi says

6 years ago
Pharma

No­body but Deer­field wants Melin­ta; No­var­tis finds a new drug dis­cov­ery part­ner

6 years ago
News Briefing

Macro­Gen­ics los­es CMO Jon Wig­gin­ton as com­mer­cial­iza­tion looms

6 years ago
People
R&D

Af­ter a trend­set­ting role in glob­al biotech ven­ture in­vest­ing, David Mott parts ways with NEA

6 years ago
People
Financing

FDA re­quires boxed warn­ing for Sin­gu­lair and its gener­ics

6 years ago
Pharma
FDA+

GSK's Em­ma Walm­s­ley award­ed £8.4M pay pack­age af­ter £2.5M rise, fi­nal­ly catch­ing up with fel­low phar­ma CEOs

6 years ago
People

How do de­pressed rats re­spond to psy­che­delics? New da­ta of­fer in­sight in­to the hu­man ex­pe­ri­ence

6 years ago
R&D

Fred Hutchin­son Cen­ter ini­ti­ates manda­to­ry work-from-home pol­i­cy as out­break roils busi­ness­es, con­fer­ences

6 years ago
Coronavirus

'Dra­mat­ic times': How did an $8B surge in NIH grants over five years change re­search on the ground (if at all)?

6 years ago
Discovery
In Focus

Vil­i­fied for high drug prices, what does the prof­itabil­i­ty of ma­jor US phar­ma com­pa­nies look like?

6 years ago
Pharma

Tack­ling in­her­it­ed blind­ness, Ed­i­tas and Al­ler­gan use CRISPR for the first time in the hu­man body

6 years ago
R&D

Bris­tol-My­ers joins forces with dig­i­tal ther­a­peu­tics co; Wear­able car­diovert­er de­fib­ril­la­tor scores $145M+ in Se­ries ...

6 years ago
News Briefing

Can re­for­mu­la­tion of an As­traZeneca castoff ri­val Takeda's new heart­burn drug? Here's a $26M bet on yes

6 years ago
Financing

AM­AG CMO hits the ex­it just as biotech search­es for new CEO to right a ship rocked by Mak­e­na con­tro­ver­sy

6 years ago
People
Pharma

Ab­b­Vie and Al­ler­gan fi­nal­ly set (rough) date for wed­ding as one par­ent agrees to the match

6 years ago
Deals
R&D
First page Previous page 847848849850851852853 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.